1
|
Tejeda-Maldonado J, García-Juárez I,
Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M,
Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF and
Carrillo-Pérez DL: Diagnosis and treatment of hepatocellular
carcinoma: An update. World J Hepatol. 7:362–376. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lencioni R, Petruzzi P and Crocetti L:
Chemoembolization of hepatocellular carcinoma. Semin Intervent
Radiol. 30:3–11. 2013. View Article : Google Scholar :
|
3
|
Kim HY and Park JW: Clinical trials of
combined molecular targeted therapy and locoregional therapy in
hepatocellular carcinoma: Past, present, and future. Liver Cancer.
3:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Furuse J, Ishii H, Nakachi K, Suzuki E,
Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese
patients with hepatocellular carcinoma. Cancer Sci. 99:159–165.
2008.
|
5
|
Chen C and Wang G: Mechanisms of
hepatocellular carcinoma and challenges and opportunities for
molecular targeted therapy. World J Hepatol. 7:1964–1970. 2015.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Bogaerts E, Heindryckx F, Vandewynckel YP,
Van Grunsven LA and Van Vlierberghe H: The roles of transforming
growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells
in primary liver tumours (Review). Int J Oncol. 44:1015–1022.
2014.PubMed/NCBI
|
7
|
Tanaka SS, Kojima Y, Yamaguchi YL,
Nishinakamura R and Tam PP: Impact of WNT signaling on tissue
lineage differentiation in the early mouse embryo. Dev Growth
Differ. 53:843–856. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Takahashi-Yanaga F: Activator or
inhibitor? GSK-3 as a new drug target. Biochem Pharmacol.
86:191–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Jamieson C, Sharma M and Henderson BR:
Targeting the β-catenin nuclear transport pathway in cancer. Semin
Cancer Biol. 27:20–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Rizvi S and Gores GJ: Molecular profiling
and research of therapeutic targets. Dig Dis. 33:586–589. 2015.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Monga SP: β-catenin signaling and roles in
liver homeostasis, Injury, and tumorigenesis. Gastroenterology.
148:1294–1310. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Fujimoto T, Tomizawa M and Yokosuka O:
SiRNA of frizzled-9 suppresses proliferation and motility of
hepatoma cells. Int J Oncol. 35:861–866. 2009.PubMed/NCBI
|
14
|
Tomizawa M, Shinozaki F, Motoyoshi Y,
Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Niclosamide
suppresses hepatoma cell proliferation via the Wnt pathway. Onco
Targets Ther. 6:1685–1693. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Handeli S and Simon JA: A small-molecule
inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma
and PPARdelta activities. Mol Cancer Ther. 7:521–529. 2008.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Davies B and Fried M: The L19 ribosomal
protein gene (RPL19): Gene organization, chromosomal mapping, and
novel promoter region. Genomics. 25:372–380. 1995. View Article : Google Scholar : PubMed/NCBI
|
17
|
Casimiro MC, Velasco-Velázquez M,
Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function
in cancer and the CDK inhibitor landscape: Past and present. Expert
Opin Investig Drugs. 23:295–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Vandooren J, Van den Steen PE and
Opdenakker G: Biochemistry and molecular biology of gelatinase B or
matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev
Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Gedaly R, Galuppo R, Daily MF, Shah M,
Maynard E, Chen C, Zhang X, Esser KA, Cohen DA, Evers BM, et al:
Targeting the Wnt/β-catenin signaling pathway in liver cancer stem
cells and hepatocellular carcinoma cell lines with FH535. PLoS One.
9:e992722014. View Article : Google Scholar
|
20
|
Wu MY, Liang RR, Chen K, Shen M, Tian YL,
Li DM, Duan WM, Gui Q, Gong FR, Lian L, et al: FH535 inhibited
metastasis and growth of pancreatic cancer cells. Onco Targets
Ther. 8:1651–1670. 2015.PubMed/NCBI
|
21
|
Iida J, Dorchak J, Lehman JR, Clancy R,
Luo C, Chen Y, Somiari S, Ellsworth RE, Hu H, Mural RJ, et al:
FH535 inhibited migration and growth of breast cancer cells. PLoS
One. 7:e444182012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Galuppo R, Maynard E, Shah M, Daily MF,
Chen C, Spear BT and Gedaly R: Synergistic inhibition of HCC and
liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and
WNT/β-catenin pathways. Anticancer Res. 34:1709–1713.
2014.PubMed/NCBI
|
23
|
Su H, Jin X, Zhang X, Zhao L, Lin B, Li L,
Fei Z, Shen L, Fang Y, Pan H, et al: FH535 increases the
radiosensitivity and reverses epithelial-to-mesenchymal transition
of radioresistant esophageal cancer cell line KYSE-150R. J Transl
Med. 13:1042015. View Article : Google Scholar : PubMed/NCBI
|